COVID-19: The Competitive Landscape for Medical Product Development

Download now: AgencyIQ – COVID Development Tracker 


The pharmaceutical and biopharmaceutical industry is scrambling to put products into development to potentially treat, cure or prevent COVID-19 infections.


Based on a review by AgencyIQ of ClinicalTrials.gov, company announcements and media reports, there are at least 65 candidates in various stages of testing to assess their potential effects against COVID-19 or SARS-CoV-2, the virus which causes the condition. These products are already at various stages of development. Some have already been approved and are being assessed for their potential to treat COVID, while others are being repurposed from other late-stage development pipelines.

 

Others are still in the very early stages of development and have not yet been tested in humans. Based on evidence from recent studies, the chances of clinical success are low. Of all drugs for infectious diseases that enter Phase 1 testing, just 26.7% go on to obtain approval. Just 31.6% of vaccines that enter Phase 1 testing go on to obtain approval. The size of the development pipeline and interest in COVID-19 may indicate that several of these products will go on to obtain approval, but the safety and efficacy of these products are far from guaranteed. As companies try to bring whatever compounds they have into clinical testing, it’s possible that few, if any, of these products will ultimately prove safe or effective.

Leave a Comment

Your email address will not be published. Required fields are marked *